ArticleFrontiers in pharmacology2021

YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS.

Jun Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.